Business, energy, technology, markets and global industry news from Business News Today

APEX trial

PharmaDeviceNews APEX trial
Representative image of hematology research and blood sample analysis, reflecting Cogent Biosciences’ bezuclastinib NDA for advanced systemic mastocytosis and the APEX trial data supporting a potential new FDA treatment option for KIT-driven mast cell disease.
Pharma & Biotech

Cogent advances third bezuclastinib FDA submission after APEX pivotal trial results

Cogent’s bezuclastinib NDA for advanced systemic mastocytosis is backed by APEX data showing 65% ORR and deep KIT-driven disease marker reductions.

Read More
Pharma & Biotech

Will Apogee Therapeutics’ APEX data shift competitive dynamics against Dupixent and Ebglyss?

Apogee Therapeutics prepares to release 52-week APEX data for zumilokibart. Discover what it could mean for eczema treatment and competition.

Read More